Breaking Down Sansure Biotech Inc. Financial Health: Key Insights for Investors

As investors scrutinize Sansure Biotech Inc. (688289.SS), the numbers tell a dynamic story: trailing twelve-month revenue of CNY 1.67 billion (up 18.65% year-over-year) and Q3 2025 revenue of CNY 375.52 million (an 18.98% increase), alongside a TTM net income of CNY 271.49 million and EPS of CNY 0.40 that sit against an operating margin of 19.45% and profit margin of 18.56%; valuation signals include a TTM P/E of 41.69 (forward P/E 25.86), P/S around 6-7 and a market cap roughly between CNY 10.72-11.84 billion, while liquidity and balance-sheet metrics show cash and equivalents of CNY 3.95 billion, a conservative debt-to-equity of 15.27%, and enterprise value near CNY 7.91 billion-factors set against historical volatility (an 84.39% revenue decline in 2023 then a 44.78% rebound in 2024), a 24.23% net income drop in 2024, and execution and regulatory risks, even as growth drivers include over 1,000 products, 1,400+ patents, 40+ global subsidiaries, the 2025 Sansure Hygene acquisition and new sepsis JV that could reshape future revenue streams-read on to unpack what these hard figures mean for potential upside, valuation, and risk exposure

Sansure Biotech Inc. (688289.SS) - Revenue Analysis

Sansure Biotech Inc. reported strong top-line momentum through 2024-2025, driven by product demand expansion and operational scaling. Key figures and trends below provide a snapshot of revenue scale, growth dynamics, productivity per employee, and market valuation relative to sales.

• TTM Revenue (ending Sep 30, 2025): CNY 1.67 billion - +18.65% year-over-year.
• Q3 2025 Quarterly Revenue: CNY 375.52 million - +18.98% vs. Q3 2024.
• Full-year 2024 Revenue: CNY 1.46 billion - +44.78% vs. 2023.
• Revenue per employee: ~CNY 711,690 based on 2,346 employees.
• Price-to-Sales (P/S) ratio: 6.56.
• Market capitalization: CNY 10.96 billion; share price: CNY 18.83 (as of Dec 11, 2025).

Observed trends indicate consistent double-digit revenue growth into 2025 after a very strong 2024 expansion. Revenue per employee and the elevated P/S suggest the market prices growth expectations into current valuation; comparative benchmarking and margin dynamics would further clarify sustainability.

• Operational implication: revenue growth + headcount scale yield ~CNY 711.7k revenue per employee, a useful productivity gauge for operational efficiency comparisons.
• Valuation implication: P/S = 6.56 and market cap CNY 10.96B reflect investor willingness to pay a premium for Sansure's sales trajectory.

For context on company strategy and guiding principles that may underpin revenue execution, see Mission Statement, Vision, & Core Values (2026) of Sansure Biotech Inc.

Sansure Biotech Inc. (688289.SS) Profitability Metrics

Key profitability indicators for Sansure Biotech Inc. provide a snapshot of how effectively the company converts revenue into earnings and utilizes its assets and equity.

• TTM Net Income: CNY 271.49 million (EPS: CNY 0.40)
• Latest quarter (ending 31-Oct-2025) Net Income: CNY 28.60 million
• EBITDA (TTM): CNY 267.89 million
• Operating Margin: 19.45%
• Profit Margin: 18.56%
• Return on Assets (ROA): 0.88%
• Return on Equity (ROE): 3.12%

Implications for investors:

• Margins (operating 19.45%, net 18.56%) show operational strength and disciplined cost control.
• EBITDA close to net income level suggests limited non-cash or non-operating distortions relative to operating profit.
• ROA and ROE indicate conservative asset and equity returns-useful when weighing growth investment vs. capital efficiency.
• Quarterly net income of CNY 28.60M confirms continuing profitability on a shorter horizon.

For broader investor context and ownership trends, see: Exploring Sansure Biotech Inc. Investor Profile: Who's Buying and Why?

Sansure Biotech Inc. (688289.SS) - Debt vs. Equity Structure

• Low leverage: 15.27% debt-to-equity implies limited reliance on external debt financing and greater financial flexibility.
• Market vs. enterprise valuation: EV (CNY 7.91B) below market cap (CNY 10.72B) signals net cash or light net debt position when combined with equity market value.
• Equity dilution: shares outstanding rose 14.18% over the past year to 574.18 million, which can affect EPS and per-share metrics.
• Book value perspective: P/B of 1.48 indicates the market values the company at a modest premium to its book equity.
• Shareholder returns and retention: 2.69% dividend yield with CNY 0.54 annualized payout alongside an earnings retained rate of 0.40% (TTM) points to a distribution-focused policy with limited reinvestment of earnings.

For mission, vision, and values context that may influence capital allocation and governance, see: Mission Statement, Vision, & Core Values (2026) of Sansure Biotech Inc.

Sansure Biotech Inc. (688289.SS) - Liquidity and Solvency

Key balance sheet and cash-flow metrics provide a snapshot of Sansure Biotech Inc.'s near-term liquidity and solvency position. The firm shows sizable cash reserves but notable declines in both cash and receivables versus the prior period, while profitability and non-cash charges support operating cash-generation analysis.

• Cash and cash equivalents: CNY 3.95 billion (down 13.85% vs. prior period)
• Accounts receivable: CNY 764.92 million (down 13.85% vs. prior period)
• Net income (TTM ending Jun 2025): CNY 232.29 million
• Depreciation & amortization (TTM ending Jun 2025): CNY 172.61 million
• Net income per cash flow statement (FY ending Dec 2024): CNY 226.27 million
• Current ratio and quick ratio: not specified in available data

Points for investor consideration:

• Cash buffer: CNY 3.95 billion remains substantial for near-term obligations despite the 13.85% decline.
• Receivables contraction: A mirrored 13.85% decrease in accounts receivable may reflect improved collections or reduced sales; monitor receivables turnover and DSO when available.
• Profit vs. cash: TTM net income (CNY 232.29m) aligns with FY2024 cash-statement net income (CNY 226.27m), while D&A (CNY 172.61m) is a meaningful non-cash add-back for cash-flow reconciliation.
• Missing ratios: Lack of disclosed current and quick ratios prevents immediate benchmarking of short-term liquidity - calculate when full current asset/liability breakdown is available.

Additional context and governance statements can be found here: Mission Statement, Vision, & Core Values (2026) of Sansure Biotech Inc.

Sansure Biotech Inc. (688289.SS) Valuation Analysis

Key valuation multiples and market metrics for Sansure Biotech Inc. provide a snapshot of how the market prices the company relative to earnings, sales, book value and cash‑flow generation.

• High TTM P/E (41.69) versus forward P/E (25.86) suggests elevated near-term earnings multiple with expected earnings growth or re-rating priced into forward estimates.
• P/S of 7.67 and P/B of 1.60 indicate the market pays a premium to sales while book value remains relatively modest compared with market value.
• EV/Revenue at 5.31 and EV/EBITDA at 29.16 point to strong revenue pricing but modest EBITDA scale relative to enterprise value, implying operational margins and cash‑flow conversion are key valuation drivers.
• Market cap discrepancies (CNY 11.84bn vs. CNY 10.72bn) alongside EV CNY 7.91bn warrant checking the data timestamp and net debt/cash adjustments when reconciling aggregates.
• Dividend yield of 2.69% with CNY 0.54 annualized payout provides an income component but is modest relative to valuation multiples-dividend sustainability should be assessed against free cash flow.

For a broader investor context and shareholder composition, see: Exploring Sansure Biotech Inc. Investor Profile: Who's Buying and Why?

Sansure Biotech Inc. (688289.SS) Risk Factors

• Revenue volatility: reported a material 84.39% decline in revenue in 2023, followed by a 44.78% rebound in 2024 - indicating high top-line sensitivity to product demand, seasonality, or one-off factors.
• Profitability pressure: net income decreased by 24.23% in 2024 versus the prior year, showing margin compression despite the 2024 revenue recovery.
• Competitive environment: intense competition in molecular diagnostics and biotech can compress pricing, increase R&D spend, and erode market share.
• Regulatory uncertainty: changes in healthcare regulation, approvals, or reimbursement policies could materially affect product launches, timing, and revenue recognition.
• Foreign‑exchange exposure: international sales and cross‑border supply chains expose Sansure to currency fluctuations that can amplify reported revenue and cost volatility.
• Market expansion and integration risks: moves into new geographies or product categories carry execution risk, potential M&A integration challenges, and upfront investment that may depress near-term returns.

• Investor considerations:
  • Model cash flow sensitivity to continued revenue swings and margin compression.
  • Stress-test scenarios for adverse regulatory outcomes or increased competitive pricing.
  • Monitor FX hedging policies and the pace/ROI of any geographic expansion.

Sansure Biotech Inc. (688289.SS) - Growth Opportunities

• Global footprint: operational scale includes over 40 subsidiaries and branches across China and key international markets, supporting distribution, regulatory access, and localized R&D.
• Product & IP strength: a portfolio of more than 1,000 developed products backed by in excess of 1,400 patents worldwide, enabling product diversification and licensing leverage.
• M&A & strategic entry: in 2025 Sansure Biotech acquired Sansure Hygene, marking its formal entrance into the biopharmaceutical sector and catalyzing the company's 'Integrated Diagnosis and Treatment' strategy.
• Partnerships for capability extension: established a joint venture with Asep Medical Holdings Inc. to accelerate deployment and validation of sepsis diagnostic technology within China's clinical market.
• Recognition & competitive edge: won first place in the iDASH 2024 Secure Genome Analysis Competition, evidencing advanced capabilities in secure genomic data analysis and computational diagnostics.

• Integrated care pathway development - combining diagnostics, therapeutics (post-2025 biopharma entry), and clinical workflow solutions to capture more value per patient.
• Sepsis and acute-care diagnostics - JV with Asep targets a high-unmet-need market where rapid diagnostics drive hospital adoption and premium pricing.
• International expansion - >40 global entities enable faster regulatory filings, local reimbursement negotiations, and cross-border commercial scale.
• Monetizing IP - >1,400 patents create avenues for licensing, cross-licensing, and defensive positioning versus competitors.
• Data-driven precision medicine - iDASH award and genomic analysis capabilities can be leveraged to offer higher-margin, software-enabled diagnostic services and companion diagnostics.

• Commercial integration of Sansure Hygene into sales and R&D pipelines to convert acquisition synergies into revenue growth.
• Clinical validation and reimbursement pathways for sepsis tests developed via the JV to ensure adoption in tertiary hospitals.
• Investment in regulatory affairs and manufacturing scale to support product launches across diverse international markets.
• Protection and monetization strategy for the patent portfolio to convert IP into recurring revenue streams.